Plain-English translation of NCT06874127 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are creating a prediction tool to help doctors understand which patients with chronic hepatitis B will see their liver scarring improve after antiviral treatment. The study will look back at medical records and test results from about 1,100 patients who have already received antiviral therapy and had liver biopsies. This tool could help doctors better predict each patient's future liver health and catch serious complications earlier.
Currently, doctors have a hard time knowing which patients will recover liver scarring and which ones are at risk for serious complications like liver cancer or liver failure. This prediction model aims to fill that gap by using existing patient data and liver stiffness measurements to better forecast outcomes.
You likely qualify if…
You likely don't qualify if…
If you join this study, researchers will review your existing medical records and test results — including blood tests, ultrasounds, and liver stiffness measurements — that you've already had as part of your hepatitis B care. You won't need to come for new visits or receive any new treatment; the study simply uses information already collected to help build and test the prediction model.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China